Company

Sialix, Inc.

Sialix, Inc. develops monoclonal and polyclonal antibodies and recombinant lab reagents for cancer research and immunology.

About

Founded in 2006 and headquartered in Newton, US, Sialix, Inc. makes monoclonal and polyclonal antibodies and recombinant lab reagents for life sciences research, sold mainly to laboratories, academic institutions and biotechnology firms. The company has pursued five deals; its latest Series B round, in June 2014, raised USD 0.53 mn, bringing the total raised to USD 0.53 mn at a stated valuation of USD 7.442 mn. Its listed stage is Series B.

2Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in